AR059984A1 - Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes - Google Patents
Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetesInfo
- Publication number
- AR059984A1 AR059984A1 ARP070101127A ARP070101127A AR059984A1 AR 059984 A1 AR059984 A1 AR 059984A1 AR P070101127 A ARP070101127 A AR P070101127A AR P070101127 A ARP070101127 A AR P070101127A AR 059984 A1 AR059984 A1 AR 059984A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- hydroxy
- substituents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula estructural (1) o una sal farmacéuticamente aceptable del mismo, en la que: cada n es independientemente 0, 1, 2 o 3; cada m es independientemente 0, 1 o 2: cada p es independientemente 0 o 1; V se selecciona de los restos del grupo de formulas (2); Ar es fenilo opcionalmente sustituido con de uno a cinco sustituyentes R1; cada R1 se selecciona independientemente del grupo constituido por halogeno, ciano, hidroxi, alquilo C1-6 opcionalmente sustituido con de uno a cinco átomos de fluor y alcoxi C1-6 opcionalmente sustituido con de uno a cinco átomos de fluor; cada R2 se selecciona independientemente del grupo constituido por hidrogeno; hidroxi; halogeno; ciano; alcoxi C1-10, en el que alcoxi está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; alquilo C1-10, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; alquenilo C2-10, en el que alquenilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; (CH2)n-arilo, en el que arilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-heteroarilo, en el que heteroarilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-heterociclilo, en el que heterociclilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de oxo, hidroxi, halogeno, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-cicloalquilo C3-6, en el que cicloalquilo está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de halogeno, hidroxi, ciano, nitro, CO2H, (alquil C1-6)oxicarbonilo, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; (CH2)n-COOH; (CH2)n-COO-alquilo C1-6; (CH2)n-NR4R5; (CH2)n-CONR4R5; (CH2)n-OCONR4R5; (CH2)n-SO2NR4R5; (CH2)n-SO2R6; (CH2)n-NR7SO2R6; (CH2)n-NR7CONR4R5; (CH2)n-NR7COR7; y (CH2)n-NR7CO2R6; en los que cualquier átomo de carbono de cualquier metileno (CH2) individual de (CH2)n está opcionalmente sustituido con de uno a dos sustituyentes que se seleccionan independientemente de fluor, hidroxi, alquilo C1-4 y alcoxi C1-4, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; R3a y R3b son cada uno independientemente hidrogeno o alquilo C1-4, opcionalmente sustituidos con de uno a cinco átomos de fluor; R4 y R5 se seleccionan cada uno independientemente del grupo constituido por hidrogeno, (CH2)m-fenilo, (CH2)m-cicloalquilo C3-6 y alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi y en el que fenilo y cicloalquilo están opcionalmente sustituidos con de uno a cinco sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; o R4 y R5 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico que se selecciona de azetidina, pirrolidina, piperidina, piperazina y morfolina, en los que dicho anillo heterocíclico está opcionalmente sustituido con de uno a tres sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor; cada R6 es independientemente alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi; R7 es hidrogeno o R6; y R8 se selecciona del grupo constituido por hidrogeno, (CH2)p-fenilo, (CH2)p-cicloalquilo C3-6 y alquilo C1-6, en el que alquilo está opcionalmente sustituido con de uno a cinco sustituyentes que se seleccionan independientemente de fluor e hidroxi y en el que fenilo y cicloalquilo están opcionalmente sustituidos con de uno a cinco sustituyentes que se seleccionan independientemente de halogeno, hidroxi, alquilo C1-6 y alcoxi C1-6, en el que alquilo y alcoxi están opcionalmente sustituidos con de uno a cinco átomos de fluor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78651806P | 2006-03-28 | 2006-03-28 | |
US83812206P | 2006-08-16 | 2006-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059984A1 true AR059984A1 (es) | 2008-05-14 |
Family
ID=38521359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101127A AR059984A1 (es) | 2006-03-28 | 2007-03-20 | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes |
Country Status (22)
Country | Link |
---|---|
US (1) | US7678905B2 (es) |
EP (1) | EP2001883B1 (es) |
JP (1) | JP5229706B2 (es) |
KR (1) | KR20090005306A (es) |
AR (1) | AR059984A1 (es) |
AT (1) | ATE554091T1 (es) |
AU (1) | AU2007243631B2 (es) |
BR (1) | BRPI0709141A2 (es) |
CA (1) | CA2646962C (es) |
CR (1) | CR10343A (es) |
DO (1) | DOP2007000051A (es) |
EA (1) | EA200870380A1 (es) |
EC (1) | ECSP088765A (es) |
GT (1) | GT200800184A (es) |
MA (1) | MA30333B1 (es) |
MX (1) | MX2008012490A (es) |
NO (1) | NO20084508L (es) |
PE (1) | PE20071104A1 (es) |
SV (1) | SV2008003045A (es) |
TN (1) | TNSN08367A1 (es) |
TW (1) | TW200806669A (es) |
WO (1) | WO2007126745A2 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007218053B2 (en) | 2006-02-15 | 2010-05-27 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
AU2007254357B2 (en) * | 2006-05-16 | 2011-07-21 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2008060488A1 (en) | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
WO2009014676A1 (en) * | 2007-07-23 | 2009-01-29 | Merck & Co., Inc. | Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2190428A4 (en) | 2007-08-21 | 2012-02-29 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
US7902376B2 (en) | 2008-01-23 | 2011-03-08 | Merck Sharp & Dohme Corp. | Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
RU2550508C2 (ru) * | 2009-09-02 | 2015-05-10 | Мерк Шарп И Доум Корп. | Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета |
EP2480551A1 (en) * | 2009-09-23 | 2012-08-01 | Pfizer Inc. | Gpr 119 modulators |
US8716482B2 (en) | 2009-09-25 | 2014-05-06 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011146358A1 (en) | 2010-05-21 | 2011-11-24 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8691832B2 (en) | 2010-12-06 | 2014-04-08 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
KR20140034861A (ko) * | 2011-06-29 | 2014-03-20 | 머크 샤프 앤드 돔 코포레이션 | 디펩티딜 펩티다제-iv 억제제의 신규한 결정질 형태 |
US9051329B2 (en) | 2011-07-05 | 2015-06-09 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9073930B2 (en) | 2012-02-17 | 2015-07-07 | Merck Sharp & Dohme | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
EP2874626A4 (en) * | 2012-07-23 | 2016-03-23 | Merck Sharp & Dohme | TREATMENT OF DIABETES BY ADMINISTRATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITORS |
WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
TWI500613B (zh) * | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
CN105085528A (zh) * | 2014-05-15 | 2015-11-25 | 成都贝斯凯瑞生物科技有限公司 | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 |
CN105518008B (zh) * | 2014-06-17 | 2018-03-27 | 海思科医药集团股份有限公司 | 氨基吡喃环衍生物及其组合物和应用 |
JP6574474B2 (ja) | 2014-07-21 | 2019-09-11 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | キラルジペプチジルペプチダーゼ−iv阻害剤の製造方法 |
EP3214079B1 (en) * | 2014-10-31 | 2020-06-24 | East China University Of Science And Technology | Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof |
CN105985357A (zh) | 2015-02-12 | 2016-10-05 | 北京赛林泰医药技术有限公司 | 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂 |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
JP6475368B2 (ja) | 2015-12-03 | 2019-02-27 | エッフェ・イ・エッセ − ファッブリカ・イタリアーナ・シンテテイチ・ソチエタ・ペル・アツィオーニF.I.S. − Fabbrica Italiana Sintetici S.p.A. | アミノテトラヒドロピラン類の製造方法 |
CN108699068B (zh) * | 2016-05-25 | 2021-01-08 | 四川海思科制药有限公司 | 一种三氟甲基取代的吡喃衍生物制备方法 |
WO2017202357A1 (zh) * | 2016-05-25 | 2017-11-30 | 四川海思科制药有限公司 | 一种三氟甲基取代的吡喃衍生物的制备方法 |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114961A (en) * | 1989-06-08 | 1992-05-19 | Merck & Co., Inc. | 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists |
JP4357293B2 (ja) * | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
JP2007513058A (ja) * | 2003-09-08 | 2007-05-24 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
JP4963671B2 (ja) * | 2004-06-21 | 2012-06-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療または予防のためのジペプチジルペプチダーゼ−iv阻害剤としてのアミノシクロヘキサン |
EP1796669B1 (en) | 2004-10-01 | 2010-09-22 | Merck Sharp & Dohme Corp. | Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
EP1819674B1 (en) | 2004-11-29 | 2011-10-05 | Merck Sharp & Dohme Corp. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
ATE540950T1 (de) | 2005-05-25 | 2012-01-15 | Merck Sharp & Dohme | Aminocyclohexane als dipeptidylpeptidase-iv- hemmer zur behandlung bzw. prävention von diabetes |
CA2619111C (en) | 2005-08-26 | 2013-04-09 | Merck & Co., Inc. | Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
AU2007218053B2 (en) * | 2006-02-15 | 2010-05-27 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
AU2007254357B2 (en) * | 2006-05-16 | 2011-07-21 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
WO2008060488A1 (en) * | 2006-11-14 | 2008-05-22 | Merck & Co., Inc. | Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
-
2007
- 2007-03-19 TW TW096109375A patent/TW200806669A/zh unknown
- 2007-03-20 DO DO2007000051A patent/DOP2007000051A/es unknown
- 2007-03-20 AR ARP070101127A patent/AR059984A1/es not_active Application Discontinuation
- 2007-03-23 PE PE2007000315A patent/PE20071104A1/es not_active Application Discontinuation
- 2007-03-26 JP JP2009502918A patent/JP5229706B2/ja not_active Expired - Fee Related
- 2007-03-26 CA CA2646962A patent/CA2646962C/en not_active Expired - Fee Related
- 2007-03-26 BR BRPI0709141-9A patent/BRPI0709141A2/pt not_active IP Right Cessation
- 2007-03-26 WO PCT/US2007/007434 patent/WO2007126745A2/en active Application Filing
- 2007-03-26 EP EP07754011A patent/EP2001883B1/en active Active
- 2007-03-26 KR KR1020087023571A patent/KR20090005306A/ko not_active Application Discontinuation
- 2007-03-26 MX MX2008012490A patent/MX2008012490A/es unknown
- 2007-03-26 AU AU2007243631A patent/AU2007243631B2/en not_active Ceased
- 2007-03-26 EA EA200870380A patent/EA200870380A1/ru unknown
- 2007-03-26 AT AT07754011T patent/ATE554091T1/de active
- 2007-03-27 US US11/728,673 patent/US7678905B2/en active Active
-
2008
- 2008-09-17 GT GT200800184A patent/GT200800184A/es unknown
- 2008-09-22 TN TNP2008000367A patent/TNSN08367A1/en unknown
- 2008-09-24 EC EC2008008765A patent/ECSP088765A/es unknown
- 2008-09-26 SV SV2008003045A patent/SV2008003045A/es not_active Application Discontinuation
- 2008-10-06 CR CR10343A patent/CR10343A/es unknown
- 2008-10-14 MA MA31288A patent/MA30333B1/fr unknown
- 2008-10-27 NO NO20084508A patent/NO20084508L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TNSN08367A1 (en) | 2009-12-29 |
EP2001883B1 (en) | 2012-04-18 |
MX2008012490A (es) | 2008-10-10 |
WO2007126745A2 (en) | 2007-11-08 |
EP2001883A2 (en) | 2008-12-17 |
EA200870380A1 (ru) | 2009-02-27 |
PE20071104A1 (es) | 2007-12-29 |
CA2646962A1 (en) | 2007-11-08 |
ECSP088765A (es) | 2008-10-31 |
TW200806669A (en) | 2008-02-01 |
JP5229706B2 (ja) | 2013-07-03 |
GT200800184A (es) | 2011-09-05 |
DOP2007000051A (es) | 2007-12-15 |
CR10343A (es) | 2008-10-29 |
WO2007126745A3 (en) | 2007-12-21 |
ATE554091T1 (de) | 2012-05-15 |
KR20090005306A (ko) | 2009-01-13 |
SV2008003045A (es) | 2009-11-09 |
CA2646962C (en) | 2011-06-21 |
US20070232676A1 (en) | 2007-10-04 |
BRPI0709141A2 (pt) | 2011-06-28 |
AU2007243631B2 (en) | 2011-11-24 |
JP2009531437A (ja) | 2009-09-03 |
NO20084508L (no) | 2008-10-27 |
MA30333B1 (fr) | 2009-04-01 |
AU2007243631A1 (en) | 2007-11-08 |
US7678905B2 (en) | 2010-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059984A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa -iv para el tratamiento o prevencion de diabetes | |
AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
PE20071009A1 (es) | Compuestos derivados de fenoxipiperidinas como antagonistas de histamina h3 | |
PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
AR073348A1 (es) | Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1 | |
AR076008A1 (es) | Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos. | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
AR072227A1 (es) | Derivados de triazinona sustituidos | |
PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
ES2662444T3 (es) | Derivado de piridina | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
RU2008142600A (ru) | Органическое соединение | |
AR048834A1 (es) | Compuestos derivados de piperidina o tropano; metodos para su preparacion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por quimioquinas (ccr5) | |
AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |